ArticleParasites & vectors2026
Efficacy of a combination of fipronil and permethrin in reducing the risk of Dirofilaria immitis transmission to dogs in field conditions.
Article in Parasites & vectors, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDirofilaria immitis is a life-threatening mosquito-borne parasite affecting dogs. Prevention mainly relies on macrocyclic lactones (MLs), but D. immitis resistance to MLs and lack of compliance may occur. Multimodal strategies combining chemoprophylaxis and vector control with insecticide and repellent products are often recommended. This study evaluated the efficacy of Frontline Tri-Act® (IVP), a topical combination of fipronil and permethrin, in preventing the transmission of D. immitis by repelling mosquitoes in naturally exposed dogs.
methodsThis study was conducted in northern Greece, in an area highly endemic for D. immitis and with seasonal (spring to fall) mosquito season. Dogs were housed in outdoor kennels to allow natural vector exposure throughout the whole study. Twenty-four healthy, heartworm-naive, Beagle dogs were randomly allocated 1:1 to an IVP or an untreated control group. Phase 1 was conducted during the mosquito season, when dogs from the IVP group were treated monthly for seven consecutive months. Phase 2 was conducted after the mosquito season, when all dogs were left untreated and diagnosed for D. immitis infection via SNAP® Leish 4Dx and Knott's test at scheduled intervals. Mosquito traps were also used to verify D. immitis infection rates, mosquito species composition and presence or absence in relation to Phase 1 and Phase 2.
resultsAt the end of the study, 7 in 12 (58.3%) untreated control dogs were heartworm-positive, while the 12 IVP treated dogs remained negative, indicating 100% preventive efficacy (p < 0.001). Several hundred mosquitoes were trapped during Phase 1 and pooled for D. immitis Polymerase Chain Reaction (PCR) detection, 8 pools in 30 (27%) were positive. No treatment-related adverse events were reported.
conclusionsFrontline Tri-Act® provided 100% protection against D. immitis transmission under natural mosquito challenge. These findings support its inclusion in multimodal strategies for heartworm prevention in endemic areas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.